Tag: Guang Liang

Regorafenib in combination with 5-FU versus bevacizumab in advance relapsed colorectal cancer

Colorectal cancer remains one of the most deadly cancers in the U.S., researchers are making steady progress against this disease. New drugs allow people with even the most advanced metastatic disease tolive longer. We did a systematic review and meta-analysis to assess response to and survival after Regorafenib treatment in patients with advance relapsed colorectal carcer. We searched MEDLINE, Embase, Ovid, and Cochrane Central databases for published studies, and we used ClinicalTrials.gov and other websites to find unpublished studies and conference abstracts.